Skip to content

Validity and Reliability of VO2-max Measurements in Persons With Parkinson's Disease

Validity and Reliability of VO2-max Measurements in Persons With Parkinson's Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05127031
Enrollment
20
Registered
2021-11-19
Start date
2021-10-01
Completion date
2022-06-01
Last updated
2023-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

Each participant would complete four test days and each test day is separated by 7-10 days. At each test day the participants would complete a graded maximal exercise test (VO2max-test), a chair rise (Linear encoder) as well as measuring of basic demographic outcomes (weight, fat%,blood pressure etc.). The first test day would further include a motor (MDS-UPDRS III) and cognitive examination (MoCA), a questionnaire about quality of life (PDQ-39) and one about depression (BDI-II). Furthermore, the first test day would include two test of walking performance (6 minutes walk test and Time Up and Go). Two of the test days would be completed while the participants are off their Parkinson disease medication for at least 12 hours, while the other two test days would be completed while on their Parkinson medication. The order of the tests would be randomized. It is hypothesized that the VO2max test would be reliable and valid when participants are on medication, while off-medication would affect the reliability and validity.

Interventions

None listed

Sponsors

University of Aarhus
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 40 year * Written informed consent * Diagnosed with idiopathic Parkinson's disease * Hoehn & Yahr ≤ 3 * Taking dopaminergic medication * Able to complete a maximal aerobic test on a bicycle

Exclusion criteria

* Dementia * Alcohol abuse * Pacemaker * Serious cardiovascular, respiratory, orthopedic or other comorbidities excluding maximal exercise participation. * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
VO2max (O2ml/min/kg) changeUp to 40 daysThe maximal oxygen consumption during and graded exercise test. Used to asses the day to day variation between two test.
VO2 plateau (Primary validity criterion)Up to 40 daysLooking at the difference between the actual measure of VO2 at the end of the VO2-max test and the predicted VO2 calculated using a linear regression.
Respiratory exchange ratio (RER) (secondary validity criterion)Up to 40 daysThe ratio between VCO2 (L/min) and VO2 (L/min)
Blood lactate (secondary validity criterion)Up to 40 daysBlood lactate level taken from a fingertip one minute after the VO2max has ended.
Maximal heart rate (beats/min) (secondary validity criterion)Up to 40 daysWe would detect the maximal heart rate at the end of the test
Rating perceived exertion (RPE) (secondary validity criterion)Up to 40 daysUsing the Borg scala, we would determine the RPE at the end of the test.

Secondary

MeasureTime frameDescription
The Montreal Cognitive Assessment (MoCA)At the first test dayParticipants have to complete different task using the MoCA.
Weight (kg)Four times (one at each visit) during af 40 days periodWe would collect information about weight using bioimpedance sensor (TANITA SC220).
Chair rise - maximal power output (W) changeUp to 40 daysThe maximal power output measured during af chair rise (Linear Encoder). Using the change between two tests to evaluate the reliability
Date of diagnosis (month and year)At first visit onlyCollecting information from when participants were diagnosed with Parkinson disease to detect disease duration (years)
MedicationAt first visit onlyWe want to know what type of medication that they use to ensure that participants fulfill the inclusion criterion
Blood pressure (systolic/diastolic) (mmHg)Four times (one at each visit) during af 40 days periodUsing a blood pressure monitor to ensure that participants do not have a blood pressure above 160/110 mmHg at test day.
Parkinson's Disease Questionnaire (PDQ-39)At the first test dayA questionnaire to evaluate the quality of life with scores ranging from 0-100 (higher scores indicating worse quality of life)
Beck Depression Inventory-II (BDI-II)At the first test dayTo evaluate depression. Scores ranges from 0-63 with higher scores indicating more severe depressive symptoms
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating scale (MDS-UPDRS) IIIAt the first test dayA motor examination done by an educated assessor. Scores ranges from 0-132 with higher scores indicating more severe motor disability.
6-minute walk test (6MWT)At the first test dayTo measure the distance, the participant is able to walk over 6 minutes using a 30 meter track.
Timed up and go (TUG)At the first test dayParticipants have to rise from a chair, walk three meters and go back and sit on the chair again as fast as possible, without running

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026